Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD (RRFT)
2. august 2018 oppdatert av: Medical University of South Carolina
Adolescents receiving RRFT and their caregivers will report significantly fewer substance use problems (quantity of use, frequency of use, and abuse symptoms) during treatment and follow-up than control adolescents who receive Treatment as Usual (TAU).
Adolescents receiving RRFT and their caregivers will report improvement in empirically-demonstrated risk and protective factors for substance use and abuse at the individual level (e.g., coping) and at each level of an adolescent's ecology (e.g., increased number of positive family activities, reduced family conflict, reduced number of peers who use drugs, improved school attendance, increased involvement in pro-social community activities) during treatment and follow-up than control adolescents who receive TAU. Adolescents receiving RRFT will experience less PTSD symptoms (per youth and caregiver reports) during treatment and follow-up than control adolescents who receive TAU. Adolescents receiving RRFT will report engaging in fewer risky sexual behaviors (e.g., increased condom use, fewer partners) during treatment and follow-up than control adolescents who receive TAU. Changes during treatment in family relations (familial cohesiveness and conflict, satisfaction with caregiver-youth relationship) and parenting practices (monitoring) will mediate changes in substance use.
Changes during treatment in emotional reactivity will mediate changes in PTSD symptoms.
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Detaljert beskrivelse
See above.
Studietype
Intervensjonell
Registrering (Faktiske)
135
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Medical University of South Carolina
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
13 år til 18 år (Barn, Voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- 1) 13-18 years old;
- 2) Presenting to LCC/HH for evaluation or treatment;
- 3) Report having experienced IPV in their lifetime, including: CSA, defined as forced or unwanted: (a) vaginal or anal penetration by an object, finger, or penis; (b) oral sex; (c) touching of the respondent's breasts or genitalia; or (d) respondents' touching of another person's genitalia; CPA, defined as having been (a) attacked or threatened with a gun, knife, or some other weapon; (b) attacked by another person with perceived intent to kill or seriously injure; (c) beaten and injured (i.e., "hurt pretty badly") by another person; (d) spanked so forcefully that it resulted in sustained welts or bruises or required medical care; or (e) cut, burned, or tied up by a caregiver as a punitive consequence; Exposure to Domestic Violence; and being victim of or bearing witness to Community Violence.
- 4) Have a memory of the incident(s);
- 5) Five or more DSM-IV PTSD symptoms;
- 6) Substance use, defined as alcohol or illicit drug use in the past 90 days per self-report and/or urine drug screen or breathalyzer.
Exclusion Criteria:
- 1) Previously identified as having a Pervasive Developmental Disability or Moderate to Severe Mental Retardation;
- 2) Actively suicidal or homicidal;
- 3) Reports active psychotic disorder
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Treatment as Usual (TAU)
Treatment as Usual (TAU) will be defined as it already exists within the community child advocacy centers.
This could include individual and/or group therapy using a variety of treatment models.
|
Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers.
In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community.
TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
Andre navn:
|
|
Eksperimentell: RRFT
RRFT is an acronym for an experimental intervention named Risk Reduction through Family Therapy.
Please see intervention description for more detail about the model.
|
RRFT is an integrative, ecologically-based approach to risk reduction and treatment.
A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed.
This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system.
Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
change in substance use problems (initiation/continuation, quantity, and abuse symptoms)
Tidsramme: 18 months
|
18 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
change in PTSD severity and symptoms
Tidsramme: 18 months
|
18 months
|
|
change in risky sexual behaviors
Tidsramme: 18 months
|
18 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Carla K Danielson, PhD, Medical University of South Carolina
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. november 2012
Primær fullføring (Faktiske)
12. juli 2018
Studiet fullført (Faktiske)
12. juli 2018
Datoer for studieregistrering
Først innsendt
15. november 2012
Først innsendt som oppfylte QC-kriteriene
13. desember 2012
Først lagt ut (Anslag)
17. desember 2012
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
3. august 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
2. august 2018
Sist bekreftet
1. august 2018
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Pro00009042
- R01DA031285-01 (U.S. NIH-stipend/kontrakt)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .